Published: 13.07.2026 at 00:01 AM,
Editor boerse-global.de
A new active substance shows significant success in studies, while microbiome research is delivering entirely new approaches.
Success for TYK2 Inhibitor: Deucravacitinib Shines
A recent market report dated July 9, 2026, confirms that the active substance Deucravacitinib has achieved its primary endpoint in the Phase III study SLE-TIT. The investigation involved 1,200 patients. After 52 weeks, participants showed a reduction in the SLEDAI-2K score by at least four points, with a relative risk reduction of 22 percent.
Secondary endpoints were also positive, with proteinuria—a marker for kidney damage—decreasing by 30 percent. Additionally, renal responder rates improved. The most common side effect noted was mild upper respiratory infections. The manufacturer is now set to submit a New Drug Application (NDA).
Combination Therapy Against Lupus Nephritis
In parallel, the pharmaceutical industry is focusing on new combinations. Aurinia Pharmaceuticals launched the Phase IV study PRESERVE on July 6, 2026, to evaluate the use of Voclosporin alongside other immunomodulators such as Belimumab, Obinutuzumab, or Anifrolumab. The aim is to achieve a complete renal response within six months, with around 150 patients with lupus nephritis participating.
The market interest is growing: Aurinia’s revenue rose by 24 percent in the first quarter of 2026 to 77.7 million USD, mainly from Voclosporin.
The recent therapeutic successes with Deucravacitinib and Voclosporin provide hope to lupus patients. Furthermore, microbiome research is opening promising pathways. Our free report summarizes the most important studies and practical tips.
Gut Bacteria Regulate the Immune System
A completely new field of research is placing the microbiome in the spotlight. Scientists from UT Southwestern published groundbreaking findings in the journal Cell Host & Microbe: Gut bacteria regulate the transport of vitamin A through a cellular network, influencing the maturation of T-cells in the lymph nodes. Disruptions in the bacterial flora can significantly impair immune development.
Another study published in Genes & Immunity identified a direct link between the bacterium Akkermansia massiliensis and the genetic predisposition for autoimmune diseases such as multiple sclerosis (MS). A lower abundance of this bacterium correlates with gene variants that weaken immune tolerance. Experts see these mechanisms as relevant for lupus as well.
Probiotics and Fermented Foods as Support
Approximately 70 percent of all immune cells reside in the intestinal mucosa. Chronic stress can increase intestinal permeability within just one to two weeks, thereby promoting systemic inflammation. An analysis published in early 2026 involving over 9,000 adults indicates that yogurt and probiotic consumption significantly reduces the risk of inflammatory sequelae.
Chronic inflammation and kidney damage burden many lupus patients. A new active substance reduces proteinuria by 30%. Discover more in our report about therapy options and how to support your microbiome through nutrition.
Experts also highlight fermented foods like sauerkraut or kimchi, which stimulate the body’s production of GLP-1 and can regulate inflammation levels. Probiotics such as L. rhamnosus or B. longum are already successfully utilized for stress-related issues.
The targeted application of specific bacterial strains in lupus therapy remains an area of ongoing research. It is clear that the regeneration of the microbiome is a long-term process, lasting eight to twelve weeks.
